- Update Jan 02, 2020 NEW YORK – Illumina and Pacific Biosciences announced Thursday after the close of the market that they have "mutually agreed" to terminate their merger agreement.
- In a joint statement, the firms cited a "lengthy regulatory approval process" and "continued uncertainty of the ultimate outcome" in their decision, which they said "is in the best interest of their respective shareholders and employees."
- Oct. 30: #1, 5; vol. 777K
Pacific Biosciences to be acquired by Illumina (ILMN) for $8.00/share in cash, or approximately $1.2 bln
With its acquisition of Pacific Biosciences, Illumina will be positioned to provide integrated workflows and novel innovations that bring together the best of both technologies to help researchers advance their discoveries faster and clinicians offer new tests economically. The transaction is subject to approval by the shareholders of Pacific Biosciences, as well as other customary closing conditions, including applicable regulatory approvals. Illumina expects to close the transaction in mid-2019.
Pacific Biosciences misses by $0.04, misses on revs;
No comments:
Post a Comment